1. CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study. Issue 11 (25th May 2014) Authors: Di Prospero, N. A.; Artis, E.; Andrade‐Gordon, P.; Johnson, D. L.; Vaccaro, N.; Xi, L.; Rothenberg, P. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 11(2014:Nov.) Page Start: 1055 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus. Issue 11 (8th July 2014) Authors: Sha, S.; Polidori, D.; Heise, T.; Natarajan, J.; Farrell, K.; Wang, S.‐S.; Sica, D.; Rothenberg, P.; Plum‐Mörschel, L. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 11(2014:Nov.) Page Start: 1087 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double‐blind, crossover study. Issue 2 (5th January 2015) Authors: Sha, S.; Polidori, D.; Farrell, K.; Ghosh, A.; Natarajan, J.; Vaccaro, N.; Pinheiro, J.; Rothenberg, P.; Plum‐Mörschel, L. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 2(2015:Feb.) Page Start: 188 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗